Dry Powder Inhalers Market: Products, Therapeutics, Players

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 1, 2017 at 6:00 AM 140

Dry Powder Inhalers Market: Products, Therapeutics, Players and Forecasts, 2024

Dublin, June 01, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Dry Powder Inhalers: Products, Therapeutics, Players and Forecasts" report to their offering. The Dry Powder Inhalers Market Report examines the rising potential of dry powder inhalation. This market is being driven by research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. The combination of improved particle properties and more efficient inhaler designs is creating new opportunities for dry powder inhalation and expanding the range of active compounds that can be effectively delivered to the lung via DPI. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient - friendly and cost -effective. Our analysis contained in the dry powder inhalers market report illustrates that inhaled administration in general, and DPI in particular, are well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and the commercialization of therapeutic drugs. Dry Powder Inhalers: Products, Therapeutics, Markets, Players and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for inhalable drugs formulated as inspirable powders and supplied in DPI devices. Provider organization business managers, healthcare administrators and investors will also benefit from this study. What You Will Learn - What inhalable drugs are supplied in powder form, how are they marketed, what are the device specifics, and who markets them? - What inhalable dry powder drugs are in late stage development, who are the developers, and what indications are they targeting? - What are the major factors driving inhaled dry powder drug/device demand? - What is the size of the market today, who are the market share leaders, and what will the market share be in 2024? - How important are drug developer-device manufacturer relationships and what are the key alliances in the industry? - What are the essential design factors, technologies and market development issues for dry powder inhalation products? - What are the significant economic, technology, and regulatory factors affecting the market for dry powder inhalers? Key Topics Covered: 1. Executive Summary 2. Inhaled Drug Therapeutics - Devices and Formulations - Market Segments and Indications - Competing Technologies - Established Therapeutic Targets - Demographics and Growth - Market Drivers - Risk Factors 3. Dry Powder Technology & Markets - Dry Powder Formulations - Particle Technology/Engineering - Dry Powder Processing - Dry Powder Packaging - DPI Product Segments - DPI Inhaler Design Categories - Reservoir Devices - Discrete Dose Devices - Proprietary Technology Devices - DPI Device Availability - Customer-specific DPI Devices - Multi-client DPI Devices - Development-stage Devices 4. DPI Product Assessment & Analysis 5. FDA Approved DPI Products - Mono-drug Products - Aclidinium - Albuterol - Budesonide - Fluticasone - Formoterol - Glycopyrronium - Indacaterol - Insulin - Loxapine - Mometasone - Salmeterol - Tiotropium - Tobramycin - Umeclidinium - Zanamivir 6. Dual Drug Products - Fluticasone+Salmeterol - Fluticasone+Vilanterol - Glycopyrronium+Indacaterol - Umeclidium+Vilanterol 7. EMA Approved DPI Products - Mono-drug Products - Aclidinium - Glycopyrronium - Indacaterol - Umeclidinium 8. Dual Drug Products - Aclidinium+Formoterol - Budesonide+Formoterol - Fluticasone+Salmeterol - Fluticasone+Vilanterol - Glycopyrronium+Indacaterol - Umeclidinium+Vianterol 9. Therapeutic Segment Analysis, Data & Forecasts - Upper Respiratory - Asthma - COPD - Bronchospasm - Systemic Indications - Hereditary Disease - Infectious Diseases - Metabolic Conditions - Neurology - Other Systemic Markets 10. Market Factors - Regulatory Issues - Device Branding - Patient Compliance and Ease of Use - Healthcare Economics 11. Company Profiles Companies Mentioned - Abdi Ibrahim - Acerus - Acorda - Actelion - Adamis - AlgiPharma AS - Alkermes - Aptar - AstraZeneca - Baxter - Bayer Healthcare - Bespak - Boehringer Ingelheim - Chiesi - CoTherix - Consort - GlaxoSmithKline - Hexal - Janssen - Kamada - Mannkind - Meda - Menarini - Merck & Co. - Merck Sharp & Dohme - NEBU-TEC - Nektar - Novartis - Orion - Pari Pharma - Pharmaxis - Ranbaxy - Recipharm - Riwisa AG - Sandoz - Savara - Schering - Skyepharma - Sosei - Telacris - Teva - Tianjin Kinnovata Pharmaceutial - UCB - United Therapeutics - Vectura - Zelos Therapeutics For more information about this report visit http://www.researchandmarkets.com/research/phrlz4/dry_powder

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Inhalers and Nebulisers, Respiratory Devices

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vijit Chao Phraya 2026: Transforming Bangkok with Light

Bangkok's Night Sky Turns into an Artistic Canvas You think light shows are done and dusted? Think again. The Vijit Chao Phraya 2026 kicks off yet another spellbinding spectacle along the beloved river, turning Bangkok's waterline into an electrifying canvas of color and culture. For a month, from November 13 to December 13, this unique event unfolds across 19 different...

Sciens Water Expands with Roberts Filter Group Buy

A Big Splash in Water Filtration When it comes to the water game, tying up with a company like Roberts Filter Group means Sciens Water isn't here to splash around; they're diving in deep. They've just snapped up an establishment that's been part of America's water infrastructure landscape for the better part of a century. That's no small potatoes. With Roberts Filter...

Qfin Faces Class Action Deadline Amid Regulatory Woes

Hit the Deck: Qfin's Legal Storm Brews When the suits begin to rumble, it’s high time to pull up a seat and watch how these chips fall. If you're parking your funds under NASDAQ:QFIN—heads up! A shareholder rights firm is bringing a class-action lawsuit, and investors perched between March 18 and August 25, 2026, should be ready to jump ship or fight. The Mighty...

Poolwerx Expands in Florida: Matt Feldt's Bold Move

A New Wave in Northeast Florida Bet you didn't expect to hear about pool care while sipping your morning coffee, but here we are. Poolwerx, the heavyweight champion in the pool service world, is pumping up its presence in the Northeast Florida landscape. Guess who’s the man behind this expansion? Matt Feldt, a Navy vet who’s traded in sonar for skimmers, has opened...

Maritime Launch's Bold Q3 Surge Amid Space Race

Rockets, Revenue, and a Bold New Path You ever hear about a spaceport tucked away in the toes of Nova Scotia, making waves with its third-quarter earnings? Well, that's exactly what's cooking over at Maritime Launch Services. These folks have managed to turn a zero into hero in a flash, reporting $5.6 million in revenue and a snug $3.5 million in net income for Q3 2026....

Data Centers: More Power-Hungry Than Thirsty

Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....

Sasol Names Stanley Subramoney as Audit Chair

Shifting Sands at Sasol's Audit Helm Ah, the boardroom dance continues. Sasol has just announced, loud and clear from Johannesburg, that Mr. Stanley Subramoney is stepping up as the new Chairman of their Audit Committee. This is no small shuffle in the deck. When it comes to keeping the books in check at big players like Sasol, you need a top-tier audit leader. Ain't no...

AI Stocks Surge Despite Boardroom Woes and Security Probe

The Boardroom Drama Versus Business Reality Who knew that board stuff could stir up as much interest as a blockbuster earnings report? But here we are, with NVIDIA Corporation (NASDAQ: NVDA) at the center of a boardroom spectacle that's enough to make some investors sweat bullets. Turns out, CEO Jensen Huang is reportedly tangled up in a foreign intelligence effort...

A Strategic Partnership to Boost Fund II Avatar Capital Partners has nabbed $156 million for their Fund II, aiming at $300 million in Japan's living space. But the real kicker? They're now rubbing elbows with GCM Grosvenor and the Teacher Retirement System of Texas. Fancy way to say they've got some serious artillery now, with GCM Grosvenor and TRS throwing weight as...

EPIC Players Seeks Sponsors for 2027 Gala & Seasons

Shining the Spotlight on Neurodivergent and Disabled Artists The curtains are about to rise for EPIC Players' 10th Anniversary Gala, and folks, it's more than just a party; it's a cause worth championing. Set for April 7, 2027, at New York's City Winery, this event is an invitation for brands to spotlight their support for Neurodivergent and Disabled artists. If you've...